STORM Therapeutics is a University of Cambridge spin-out, translating the ground-breaking work of Professors Tony Kouzarides ...
STORM Therapeutics raises $56M Series C and doses first patient in Phase 2 sarcoma trial of STC-15, the world’s first RNA ...
For patients with advanced solid tumors harboring specific genetic alterations, the first-in-class synthetic lethal combination of WEE1 inhibitor zedoresertib plus PKMYT1 inhibitor lunresertib ...
STORM Therapeutics, a Cambridge-based clinical stage company targeting RNA modifications to reprogram cells and develop novel ...
First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients ...
Storm Therapeutics raises $56M in Series C funding to accelerate cancer therapy development and expand its innovative ...
At AACR, a bold use of CAR-T raises hopes and provocative questions about its use in smoldering multiple myeloma.
Detailed price information for Zentalis Pharmaceuticals Inc (ZNTL-Q) from The Globe and Mail including charting and trades.
This important paper substantially advances our understanding of how Molidustat may work, beyond its canonical role, by identifying its therapeutic targets in cancer. This study presents a compelling ...
Detailed price information for Ascentage Pharma Group Intl ADR (AAPG-Q) from The Globe and Mail including charting and trades.
Neck muscles, brain microarchitecture and the menstrual cycle are factors in why the genders suffer and recover from ...
Columnist Dr Henar Hevia, J&J Innovative Medicine, explores why oncology’s future hinges not on new treatments, but on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results